Dabigatran for stroke prevention and treatment of blood clots

Dabigatran etexilate capsules are an oral anticoagulant used primarily to reduce the risk of stroke and systemic embolism in adults with non-valvular atrial fibrillation. They are also approved for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults, including prevention after hip replacement surgery. Additionally, dabigatran is indicated for treatment and recurrence risk reduction of venous thromboembolic events in pediatric patients aged 8 to less than 18 years who have been previously anticoagulated.

Dabigatran etexilate capsules have the following approved uses:

• Reducing the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.
• Treating deep venous thrombosis (DVT) and pulmonary embolism (PE) in adults after 5-10 days of initial parenteral anticoagulant therapy.
• Reducing the risk of recurrence of DVT and PE in adults who have completed prior treatment.
• Preventing DVT and PE in adult patients after hip replacement surgery.
• Treating venous thromboembolic events (VTE) in pediatric patients aged 8 to less than 18 years following at least 5 days of parenteral anticoagulation.
• Reducing the risk of recurrence of VTE in pediatric patients aged 8 to less than 18 years previously treated.

Dabigatran etexilate mesylate

Dabigatran etexilate is a direct thrombin inhibitor. It works by blocking thrombin, an enzyme that plays a central role in blood clot formation. By inhibiting thrombin, dabigatran helps prevent the formation and growth of blood clots, thereby reducing the risk of stroke, embolism, and venous thromboembolic events.

Adult Dosage

• Non-valvular atrial fibrillation: For patients with creatinine clearance (CrCl) > 30 mL/min, 150 mg orally twice daily; for CrCl 15-30 mL/min, 75 mg twice daily. Dosing recommendations are not provided for CrCl < 15 mL/min or dialysis.
• Treatment of DVT and PE: 150 mg orally twice daily after 5-10 days of parenteral anticoagulant for patients with CrCl > 30 mL/min. No dosing recommendation for CrCl ≤ 30 mL/min or dialysis.
• Reduction in recurrence risk of DVT and PE: 150 mg orally twice daily after prior treatment if CrCl > 30 mL/min. Not recommended for CrCl ≤ 30 mL/min or dialysis.
• Prophylaxis post-hip replacement surgery: 110 mg orally 1-4 hours after surgery and hemostasis, then 220 mg once daily for 28-35 days (CrCl > 30 mL/min). No dosing for CrCl ≤ 30 mL/min or dialysis.
• Adjustments with P-gp inhibitors (dronedarone, ketoconazole): Reduce dose to 75 mg twice daily if CrCl 30-50 mL/min. Avoid coadministration if CrCl < 50 mL/min.

Pediatric Dosage (8 to <18 years)

• Weight-based dosing twice daily after at least 5 days of parenteral anticoagulant for treatment or after prior treatment for recurrence risk reduction. Dosage is adjusted by weight ranging from 75 mg to 260 mg twice daily as outlined in a provided dosing table.
• Avoid use in pediatric patients with estimated glomerular filtration rate (eGFR) < 50 mL/min/1.73 m² due to lack of data and risk of increased exposure.

Administration Instructions

• Swallow capsules whole with a full glass of water; do not break, chew, or open capsules.
• Dosing interval should be approximately 12 hours apart, morning and evening.
• If a dose is missed, take as soon as possible on the same day; skip if less than 6 hours before next dose; do not double doses.
• Consider taking with food if gastrointestinal symptoms occur.

Conversion and Discontinuation

• When switching from warfarin, discontinue warfarin and start dabigatran when INR < 2.0.
• When switching to warfarin, start warfarin 1 to 3 days before stopping dabigatran depending on renal function; INR monitoring is reliable only 2 days after stopping dabigatran.
• When transitioning from or to parenteral anticoagulants, follow timing guidelines to avoid gaps or overlaps.
• Discontinue 1-2 days (CrCl ≥ 50 mL/min) or 3-5 days (CrCl < 50 mL/min) before invasive procedures to reduce bleeding risk.

Boxed Warnings

• Increased risk of thrombotic events with premature discontinuation: Stopping dabigatran without appropriate alternative anticoagulation increases risk of clotting, stroke, and embolism.
• Spinal/Epidural hematoma risk: Patients receiving neuraxial anesthesia or undergoing spinal puncture while on dabigatran are at risk for spinal or epidural hematomas, which can cause paralysis. Risk factors include use of epidural catheters, concurrent drugs affecting hemostasis (NSAIDs, platelet inhibitors, other anticoagulants), history of spinal procedures or deformities, and the timing of dabigatran dosing relative to procedures.

Monitoring

• Monitor closely for signs of neurological impairment after spinal procedures; urgent intervention is required if hematoma is suspected.
• Assess renal function before starting and periodically during treatment, as renal impairment affects dosing and safety.

Use in Procedures

• Consider benefit-risk before neuraxial interventions in patients on or to be started on dabigatran.
• Temporary discontinuation is advised before surgery to minimize bleeding risk.

Common and Serious Reactions

• Bleeding events are the most significant adverse effect, ranging from minor bleeding (e.g., bruising, nosebleeds) to serious, potentially fatal hemorrhages.
• Spinal or epidural hematomas can occur in patients receiving neuraxial anesthesia or spinal puncture, potentially causing paralysis.

• Concomitant use with P-glycoprotein (P-gp) inhibitors such as dronedarone or systemic ketoconazole increases dabigatran exposure and bleeding risk, requiring dose reduction or avoidance depending on kidney function.
• Use cautiously with other drugs that affect hemostasis, including NSAIDs, platelet inhibitors, and other anticoagulants, due to increased risk of bleeding.